Disparities in Hepatocellular Carcinoma Incidence in California: An Update.
Adult
Aged
Aged, 80 and over
Asian
/ statistics & numerical data
California
/ epidemiology
Carcinoma, Hepatocellular
/ epidemiology
Cohort Studies
Female
Health Status Disparities
Hispanic or Latino
/ statistics & numerical data
Humans
Incidence
Liver Neoplasms
/ epidemiology
Male
Middle Aged
SEER Program
/ statistics & numerical data
Sex Factors
Journal
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
ISSN: 1538-7755
Titre abrégé: Cancer Epidemiol Biomarkers Prev
Pays: United States
ID NLM: 9200608
Informations de publication
Date de publication:
01 2020
01 2020
Historique:
received:
21
05
2019
revised:
01
08
2019
accepted:
04
11
2019
pubmed:
14
11
2019
medline:
12
1
2021
entrez:
14
11
2019
Statut:
ppublish
Résumé
Given changes in hepatocellular carcinoma (HCC) incidence and the ethnodemographic landscape, we analyzed recent HCC incidence patterns and trends in California. Using 47,992 primary, invasive HCC cases diagnosed from 1988 to 2014 from the California Cancer Registry, we calculated age-adjusted incidence rates (IR), annual percent change (APC), and 95% confidence intervals (CI) by sex, race/ethnicity, and nativity among Hispanics and Asian ethnic groups. Compared with non-Hispanic Whites (NHW), all other racial/ethnic groups had higher HCC incidence. Vietnamese had the highest IRs (males: 47.4, 95% CI, 45.3-49.5; females: 14.1, 95% CI, 13.0-15.3). Foreign-born Chinese, Japanese, Korean, and Vietnamese had higher incidence than U.S.-born. The reverse was observed for Hispanic males, whereas no differences by nativity were seen for Hispanic females. IRs increased most for NHWs. Among Asians, male and female Filipinos and Japanese males experienced rate increases, whereas male and female Koreans and Chinese males experienced rate decreases. U.S.-born male and female Hispanics and Japanese had higher APCs than foreign-born, as did Filipino males, whereas Chinese males had a reverse pattern. Annual increases in HCC incidence slowed down in recent years for U.S.-born Hispanic males and females and stabilized among male NHWs and non-Hispanic Blacks. For some Asian groups, early time periods exhibited increasing/stable APCs, whereas later time periods showed decreasing APCs. We found significant racial/ethnic and nativity differences in HCC IRs and trends. With changing trends, closer surveillance of HCC incidence by disaggregated race/ethnicity and nativity is warranted among Hispanics and Asians.
Sections du résumé
BACKGROUND
Given changes in hepatocellular carcinoma (HCC) incidence and the ethnodemographic landscape, we analyzed recent HCC incidence patterns and trends in California.
METHODS
Using 47,992 primary, invasive HCC cases diagnosed from 1988 to 2014 from the California Cancer Registry, we calculated age-adjusted incidence rates (IR), annual percent change (APC), and 95% confidence intervals (CI) by sex, race/ethnicity, and nativity among Hispanics and Asian ethnic groups.
RESULTS
Compared with non-Hispanic Whites (NHW), all other racial/ethnic groups had higher HCC incidence. Vietnamese had the highest IRs (males: 47.4, 95% CI, 45.3-49.5; females: 14.1, 95% CI, 13.0-15.3). Foreign-born Chinese, Japanese, Korean, and Vietnamese had higher incidence than U.S.-born. The reverse was observed for Hispanic males, whereas no differences by nativity were seen for Hispanic females. IRs increased most for NHWs. Among Asians, male and female Filipinos and Japanese males experienced rate increases, whereas male and female Koreans and Chinese males experienced rate decreases. U.S.-born male and female Hispanics and Japanese had higher APCs than foreign-born, as did Filipino males, whereas Chinese males had a reverse pattern. Annual increases in HCC incidence slowed down in recent years for U.S.-born Hispanic males and females and stabilized among male NHWs and non-Hispanic Blacks. For some Asian groups, early time periods exhibited increasing/stable APCs, whereas later time periods showed decreasing APCs.
CONCLUSIONS
We found significant racial/ethnic and nativity differences in HCC IRs and trends.
IMPACT
With changing trends, closer surveillance of HCC incidence by disaggregated race/ethnicity and nativity is warranted among Hispanics and Asians.
Identifiants
pubmed: 31719066
pii: 1055-9965.EPI-19-0560
doi: 10.1158/1055-9965.EPI-19-0560
pmc: PMC6986425
mid: NIHMS1542653
doi:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
79-87Subventions
Organisme : NCI NIH HHS
ID : HHSN261201800032C
Pays : United States
Organisme : NCI NIH HHS
ID : HHSN261201800009C
Pays : United States
Organisme : NCCDPHP CDC HHS
ID : NU58DP006344
Pays : United States
Organisme : NCI NIH HHS
ID : HHSN261201800015I
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA023100
Pays : United States
Organisme : NCI NIH HHS
ID : HHSN261201800032I
Pays : United States
Organisme : NCI NIH HHS
ID : HHSN261201800015C
Pays : United States
Organisme : NCI NIH HHS
ID : HHSN261201800009I
Pays : United States
Informations de copyright
©2019 American Association for Cancer Research.
Références
Cancer. 2016 Jun 1;122(11):1757-65
pubmed: 26998818
Gastroenterology. 2012 May;142(6):1264-1273.e1
pubmed: 22537432
Epidemiol Rev. 2007;29:6-28
pubmed: 17510091
Clin Infect Dis. 2012 Oct;55(8):1047-55
pubmed: 22875876
Clin Gastroenterol Hepatol. 2018 Feb;16(2):198-210.e2
pubmed: 28970148
J Natl Cancer Inst. 2019 Jun 1;111(6):550-556
pubmed: 30544184
Cancer. 2016 May 1;122(9):1444-52
pubmed: 26916271
Cancer Epidemiol Biomarkers Prev. 2010 Dec;19(12):3106-18
pubmed: 20940276
Stat Methods Med Res. 2006 Dec;15(6):547-69
pubmed: 17260923
Am J Gastroenterol. 2003 Sep;98(9):2060-3
pubmed: 14499788
Am J Epidemiol. 2013 Feb 15;177(4):333-42
pubmed: 23355498
Cancer. 2016 Aug 15;122(16):2512-23
pubmed: 27195481
Hepatology. 2002 Nov;36(5):1206-13
pubmed: 12395331
Am J Public Health. 2010 Apr 1;100 Suppl 1:S125-31
pubmed: 20147696
J Natl Cancer Inst. 2018 Nov 1;110(11):1259-1269
pubmed: 29617913
Cancer Epidemiol Biomarkers Prev. 2010 May;19(5):1261-8
pubmed: 20447919
J Natl Med Assoc. 2004 Sep;96(9):1185-92
pubmed: 15481746
Am J Epidemiol. 2002 Feb 15;155(4):323-31
pubmed: 11836196
Br J Cancer. 2007 Oct 8;97(7):1005-8
pubmed: 17700568
J Gastroenterol. 2017 Feb;52(2):164-174
pubmed: 27637587
Dig Dis Sci. 2016 May;61(5):1214-25
pubmed: 27038448
Hepatology. 2004 Dec;40(6):1387-95
pubmed: 15565570
Am J Gastroenterol. 2015 Sep;110(9):1306-14; quiz 1315
pubmed: 26215532
Ethn Dis. 2009 Summer;19(3):288-92
pubmed: 19769011
Liver Int. 2019 Apr;39(4):748-757
pubmed: 30597715
Am J Gastroenterol. 2013 Aug;108(8):1314-21
pubmed: 23752878
Ann Intern Med. 2013 Sep 3;159(5):349-57
pubmed: 23798026
Life Sci. 2013 Jan 17;92(1):3-9
pubmed: 23123447
Hepatology. 2007 Oct;46(4):1034-40
pubmed: 17654490
J Clin Oncol. 2016 May 20;34(15):1787-94
pubmed: 27044939
Hepatology. 2015 Sep;62(3):932-54
pubmed: 26111063
Aliment Pharmacol Ther. 2013 May;37(10):921-36
pubmed: 23557103
Ann Intern Med. 2006 May 16;144(10):705-14
pubmed: 16702586
J Hepatol. 2005 Feb;42(2):218-24
pubmed: 15664247
Ann Intern Med. 2014 Jul 1;161(1):58-66
pubmed: 24863637
J Natl Cancer Inst. 2013 Aug 7;105(15):1096-110
pubmed: 23878350
Cancer. 2018 Sep 1;124(17):3551-3559
pubmed: 30113700
J Infect Dis. 2010 Jul 15;202(2):192-201
pubmed: 20533878
Int J Obes (Lond). 2011 Mar;35(3):393-400
pubmed: 20680014